In the previous article, I wrote about the moment optionality begins to narrow in MedTech scale-ups. The natural question for boards is what determines whether that shift is recognised early, or only noticed once timelines begin to stretch.

Across portfolios, the answer is rarely capital, rarely technology, and it is almost never effort. The hidden variable is how quickly the organisation interprets the signals already arriving from its evidence environment.

Most MedTech scale-ups believe progress is measured by milestones.

• Regulatory submissions.
• Clinical datasets.
• First hospital adoption.
• Early reimbursement conversations.

These are visible markers, and they matter. But specialist investors know something else.

Enterprise value in MedTech does not move smoothly with activity. It moves in steps tied to regulatory and evidence milestones, each of which changes how the outside world interprets the product. (Strategic Solutions for MedTech)

That means trajectory begins shifting before performance indicators catch up. The question is whether the leadership structure sees that shift early enough.

Early in development, signals point in several directions at once.

1. Clinical positioning remains flexible.
2. Regulatory classification may still evolve.
3. Market sequencing is still open to influence.

Optionality is wide. Later, signals begin settling.

• A comparator becomes decisive.
• A claim needs stronger support.
• A regulatory route becomes more realistic than the others.

None of this feels dramatic at the time, but the environment is beginning to express a preference. And once the environment expresses a preference, trajectory begins settling around it.

This is where some organisations move cleanly through scale. Others begin experiencing friction. The difference is interpretation speed. Regulation in MedTech is often described as a compliance exercise.

In practice, it behaves more like a development framework that shapes product decisions from the beginning of the lifecycle rather than at the submission stage. (QbD Group)

That distinction matters. If regulation shapes development, then signals about trajectory appear earlier than most teams expect. 

Boards that recognise those signals early retain flexibility longer.

Boards that recognise them late often experience narrowing optionality as execution difficulty rather than structural movement.

The evidence environment itself has changed significantly over the last decade. 

Under the transition from the Medical Device Directive to the Medical Device Regulation, technical documentation expectations have expanded, clinical evidence requirements have increased, and notified-body timelines have extended from roughly six to nine months to twelve to eighteen months in many cases. (qservegroup.com)

Across Europe, more than half of manufacturers report portfolio reductions as a direct consequence of MDR compliance pressure. (Skills Alliance) These are not administrative effects. They are trajectory effects.

They influence which products reach the market, which claims remain viable, and which strategies survive contact with regulatory reality.

From a portfolio perspective, something important follows from this. Signals about the future shape of a company rarely arrive through performance data first.

• They arrive through interpretation.
• Regulators express them through tone.
• Clinicians express them through adoption confidence.
• Investors express them through milestone sensitivity.
• Study design expresses them through constraint.

The leadership architecture interpreting those signals determines how early the organisation adapts.

Across Signal Council conversations I have been part of recently, particularly where several scale-stage companies are being considered side by side, this pattern appears repeatedly.

The companies that retain momentum are not always the fastest. They are the ones that recognise earlier which version of their product the environment is already beginning to support. That recognition changes behaviour.

• Clinical strategy tightens earlier.
• Claims discipline improves earlier.
• Regulatory positioning stabilises earlier.
• Commercial sequencing becomes clearer earlier.

From the outside, this looks like execution strength. In reality, it is interpretation strength.

This is why the hidden variable inside many MedTech scale-ups right now is alignment between trajectory signals and leadership architecture.

Not capability nor ambition but alignment.

Early leadership teams are usually excellent at building possibility. Later stages require something different.

They require the ability to recognise which possibilities remain genuinely open and which only appear open because the evidence conversation has not yet caught up with them.

Experienced portfolio Chairs tend to recognise this moment instinctively.

• They begin listening less for milestone movement and more for tone movement.
• They notice when regulatory conversations become more specific.
• They notice when reimbursement logic begins favouring one positioning story over another.
• They notice when optionality is still present, but no longer symmetrical.

At that point, the strategic question changes. It is no longer simply whether the company is progressing.

It becomes whether the organisation interpreting the signals is configured for the chapter it has already entered.

In MedTech scale-ups, trajectory rarely changes suddenly. It settles gradually around the interpretation the organisation is able to support. Progress remains visible and signals arrive earlier. 

Alignment determines whether the two move together. That alignment is often the first place experienced boards can see the future becoming predictable before performance makes it obvious.

FAQs

What is the “hidden variable” in MedTech scale-ups?

The speed at which leadership teams interpret regulatory, clinical and investor signals compared with how quickly those signals are evolving around the product.

Why does interpretation matter more than execution speed at scale stage?

Because enterprise value in MedTech moves in steps tied to regulatory and evidence milestones rather than continuous operational progress. (Strategic Solutions for MedTech)

How has MDR changed trajectory risk for scale-ups?

MDR increased documentation expectations, clinical evidence requirements and notified-body review timelines, extending conformity assessment in many cases to 12–18 months and forcing portfolio rationalisation across the sector. (qservegroup.com)

Why do some companies recognise trajectory shifts earlier than others?

Because leadership architecture determines how signals from regulators, clinicians and investors are interpreted and acted upon.

What should portfolio Chairs listen for early?

Changes in tone around claims, comparators, reimbursement logic and regulatory expectations. These usually appear before performance indicators move.

About the Author

Harun Rabbani works with MedTech boards and investors at the points where leadership architecture begins influencing regulatory trajectory, valuation timing and market-access credibility.

Having built his career inside organisations such as Olympus and Gyrus, he now supports scale-stage medical technology companies as they move from early validation to adoption readiness. His work focuses on helping boards interpret trajectory signals early, while strategic optionality still exists.

Through his work with portfolio leaders and Signal Council-level conversations across the sector, he helps organisations align leadership structure with the evidence environment shaping their future.

#MedTechLeadership #MedicalDeviceStrategy #MedTechScaleUps #HealthTechGovernance #MedTechInvestment